Relation between crack growth behaviour and crack front morphology under hold-time conditions in DA Inconel 718

The crack growth behaviour of Direct Aged Inconel 718 was studied at 550 °C. Experiments were carried out under pure fatigue cycles, hold-time cycles of different durations and a mix of both. Hold-time cycles were systematically associated with complex crack front morphologies. A new numerical approach was developed to assess the effect of crack front morphology on the direct current potential drop technique, mechanical fields at the crack tip and ultimately, measured crack growth rates. Using this approach, a clear relation was established between crack front morphology and its evolution, and the crack growth behaviour under hold-time conditions. Complex crack front morphologies are demonstrated to be responsible for increased crack growth rates. From this, a crack growth mechanism under hold-time conditions is proposed. Finally, the numerical framework here presented is to be considered as a new, easily reproducible, way to properly analyse experimental data when dealing with complex loading cycles and complex crack front morphologies

Finite-size scaling in thin Fe/Ir(100) layers

The critical temperature of thin Fe layers on Ir(100) is measured through M\"o{\ss}bauer spectroscopy as a function of the layer thickness. From a phenomenological finite-size scaling analysis, we find an effective shift exponent lambda = 3.15 +/- 0.15, which is twice as large as the value expected from the conventional finite-size scaling prediction lambda=1/nu, where nu is the correlation length critical exponent. Taking corrections to finite-size scaling into account, we derive the effective shift exponent lambda=(1+2\Delta_1)/nu, where Delta_1 describes the leading corrections to scaling. For the 3D Heisenberg universality class, this leads to lambda = 3.0 +/- 0.1, in agreement with the experimental data. Earlier data by Ambrose and Chien on the effective shift exponent in CoO films are also explained.Comment: Latex, 4 pages, with 2 figures, to appear in Phys. Rev. Lett

Reproducible formation of single magnetic bubbles in an array of patterned dots

International audienceThe formation conditions of single magnetic bubbles through in-plane field demagnetizationare investigated in an array of Co/Ni circular dots by magnetic force microscopy andcompared to micromagnetic calculations. We demonstrate high success rates in nucleatingstable bubbles. The efficiency of single bubble formation is found to depend not only on thedot size, material thickness and intrinsic material parameters but also on the bubble nucleationpath. Experimental phase diagrams and micromagnetic calculations highlight the influenceof the starting in-plane field amplitude and dipolar interactions in stabilizing the bubble.The identification of a systematic procedure for controlling nucleation of single bubbles,multidomain states or a uniform state is important from a technological point of view, openinga path toward the realization of reprogrammable magnonic crystals for the control of spinwavepropagation

Chapitre 10 - Co-conception de changements techniques et organisationnels au sein des systèmes agricoles

Résumé. Les mutations en cours au sein de l’agriculture interrogent les travaux et les méthodes relatifs à la conception de systèmes agricoles innovants. Ce chapitre analyse la spécificité de cinq démarches de co-conception de systèmes techniques testées en France et dans différents pays d’Afrique et d’Amérique latine. Elles se basent sur des interactions fortes entre les acteurs impliqués dans ces démarches, facilitées par une diversité d’objets intermédiaires tels que la modélisation ou l’expérimentation agronomique en milieu paysan. Elles ont permis de produire des connaissances opérationnelles et scientifiques sur des changements techniques et leurs conditions de mise en œuvre à l’échelle de l’exploitation ainsi que sur les conditions institutionnelles favorables à l’émergence de nouveaux systèmes. Ces démarches mobilisent des compétences ne relevant pas seulement de l’agronomie. L’intégration de chercheurs relevant des sciences humaines s’avère centrale, en particulier pour analyser comment hybrider des connaissances multiples en vue d’accompagner l’innovation au sein des exploitations et des territoires

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a lesser extent, SMS2, encoded by the SGMS1 and SGMS2 genes, respectively. Alternatively, ceramide can be converted to glucosylceramide (GlcCer) by the GlcCer synthase (GCS), encoded by the UGCG gene. Herein, we provide evidence for the first time that SMS1 is frequently downregulated in various solid cancers, more particularly in melanoma. Accordingly, various human melanoma cells displayed a SL metabolism signature associated with (i) a robust and a low expression of UGCG and SGMS1/2, respectively, (ii) higher in situ enzyme activity of GCS than SMS, and (iii) higher intracellular levels of GlcCer than SM. SMS1 was expressed at low levels in most of the human melanoma biopsies. In addition, several mutations and increased CpG island methylation in the SGMS1 gene were identified that likely affect SMS1 expression. Finally, low SMS1 expression was associated with a worse prognosis in metastatic melanoma patients. Collectively, our study indicates that SMS1 downregulation in melanoma enhances GlcCer synthesis, triggering an imbalance in the SM/GlcCer homeostasis, which likely contributes to melanoma progression. Evaluating SMS1 expression level in tumor samples might serve as a biomarker to predict clinical outcome in advanced melanoma patients

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

A B S T R A C T Purpose Mitoxantrone-corticosteroid is currently the standard palliative treatment in hormone-refractory prostate cancer (HRPC) patients. Recent clinical trials documented the high activity of the docetaxel-estramustine combination. We conducted a randomized phase II study to evaluate prostate-specific antigen (PSA) response (primary end point) and safety of two docetaxelestramustine-prednisone (DEP) regimens and mitoxantrone-prednisone (MP). Patients and Methods One hundred thirty metastatic HRPC patients were randomly assigned to receive docetaxel (70 mg/m 2 on day 2 or 35 mg/m 2 on days 2 and 9 of each 21-day cycle) and estramustine (280 mg PO tid on days 1 through 5 and 8 through 12) or mitoxantrone 12 mg/m 2 every 3 weeks; all patients received prednisone (10 mg daily). Results One hundred twenty-seven patients were assessable for PSA response and safety. A Ն 50% PSA decline was found in a greater percentage of patients in the docetaxel arms (67% and 63%) compared with MP (18%; P ϭ .0001). Median time to PSA progression was five times longer with DEP than with MP (8.8 and 9.3 v 1.7 months, respectively; P ϭ .000001). Overall survival was better in the docetaxel arms (18.6 and 18.4 months) compared with the MP arm (13.4 months), but not significantly so (P ϭ .3). Crossover rates differed significantly among treatment arms (16%, 10%, and 48% in arms A, B, and C, respectively; P ϭ .00001). Treatment-related toxicities were mild and mainly hematologic. Conclusion The results of this randomized phase II study showed significantly higher PSA decline Յ 50% and longer times to progression in HRPC patients receiving DEP-based chemotherapy than MP, and that DEP could be proposed in this setting

Innovation et développement dans les systèmes agricoles et alimentaires

L’innovation est souvent présentée comme l’un des principaux leviers pour promouvoir un développement plus durable et plus inclusif. Dans les domaines de l’agriculture et de l’alimentation, l’innovation est marquée par des spécificités liées à sa relation à la nature, mais aussi à la grande diversité d’acteurs concernés, depuis les agriculteurs jusqu’aux consommateurs, en passant par les services de recherche et de développement. L’innovation émerge des interactions entre ces acteurs, qui mobilisent des ressources et produisent des connaissances dans des dispositifs collaboratifs, afin de générer des changements. Elle recouvre des domaines aussi variés que les pratiques de production, l’organisation des marchés, ou les pratiques alimentaires. L’innovation est reliée aux grands enjeux de développement : innovation agro-écologique, innovation sociale, innovation territoriale, etc. Cet ouvrage porte un regard sur l’innovation dans les systèmes agricoles et alimentaires. Il met un accent particulier sur l’accompagnement de l’innovation, en interrogeant les méthodes et les organisations, et sur l’évaluation de l’innovation au regard de différents critères. Il s’appuie sur des réflexions portées par différentes disciplines scientifiques, sur des travaux de terrain conduits tant en France que dans de nombreux pays du Sud, et enfin sur les expériences acquises en accompagnant des acteurs qui innovent. Il combine des synthèses sur l’innovation et des études de cas emblématiques pour illustrer les propos. L’ouvrage est destiné aux enseignants, professionnels, étudiants et chercheurs

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Abstract: Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers